Clinical applications of buprenorphine depot injection for opioid use disorder

被引：2
|
作者：
Allikmets, Silvia [1 ]
Vink, Jasper Pieter [2 ]
机构：
[1] Kings Coll London, Sch Med, London, England
[2] Guys & St Thomas NHS Fdn Trust, London, England
来源：
ADDICTION | 2020年 / 115卷 / 01期
关键词：
Buprenorphine; depot; methadone; opioid use disorder; subcutaneous; sublingual;
D O I：
10.1111/add.14818
中图分类号：
R194 [卫生标准、卫生检查、医药管理];
学科分类号：
摘要：
引用
收藏
页码：190 / 190
页数：1
相关论文
共 50 条
  • [1] Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation
    Ling, Walter
    Shoptaw, Steve
    Goodman-Meza, David
    SUBSTANCE ABUSE AND REHABILITATION, 2019, 10 : 69 - 78
  • [2] Monthly Buprenorphine Injection Approved for Opioid Use Disorder
    Voelker, Rebecca
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (03): : 220 - 220
  • [3] Evaluation of the Effects of a Monthly Buprenorphine Depot Subcutaneous Injection on QT Interval During Treatment for Opioid Use Disorder
    Schmith, Virginia D.
    Curd, Laura
    Lohmer, Lauren R. L.
    Laffont, Celine M.
    Andorn, Anne
    Young, Malcolm A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (03) : 576 - 584
  • [4] Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences
    Neale, Joanne
    Tompkins, Charlotte N. E.
    Strang, John
    DRUG AND ALCOHOL REVIEW, 2019, 38 (05) : 510 - 518
  • [5] Depot Buprenorphine Injection in the Management of Opioid Use Disorder: From Development to Implementation (vol 10, pg 69, 2019)
    Ling, W.
    Shoptaw, S.
    Goodman-Meza, D.
    SUBSTANCE ABUSE AND REHABILITATION, 2020, 11 : 19 - 20
  • [6] Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder
    Tompkins, Charlotte N. E.
    Neale, Joanne
    Strang, John
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2019, 104 : 64 - 71
  • [7] SUBSTITUTION THERAPY WITH FLEXIBLE-DOSE DEPOT BUPRENORPHINE INJECTION TO TREAT OPIOID USE DISORDER IN THE UNITED KINGDOM: A PHARMACOECONOMIC ASSESSMENT
    Tiberg, R.
    Jensen, R.
    Sanjurjo, V
    Carter, J. A.
    VALUE IN HEALTH, 2017, 20 (09) : A711 - A711
  • [8] Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis
    Andorn, Anne C.
    Haight, Barbara R.
    Shinde, Sunita
    Fudala, Paul J.
    Zhao, Yue
    Heidbreder, Christian
    Learned, Susan M.
    Fox, Norma Lynn
    Nadipelli, Vijay R.
    Hassman, David
    Rutrick, Daniel
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2020, 40 (03) : 231 - 239
  • [9] Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder A Randomized Clinical Trial
    Lofwall, Michelle R.
    Walsh, Sharon L.
    Nunes, Edward V.
    Bailey, Genie L.
    Sigmon, Stacey C.
    Kampman, Kyle M.
    Frost, Michael
    Tiberg, Fredrik
    Linden, Margareta
    Sheldon, Behshad
    Oosman, Sonia
    Peterson, Stefan
    Chen, Michael
    Kim, Sonnie
    JAMA INTERNAL MEDICINE, 2018, 178 (06) : 764 - 773
  • [10] eComparison of oral buprenorphine/naloxone, depot buprenorphine and methadone for patients released from custodial settings with opioid use disorder
    Shi, Avelyn
    Naz, Rokshar
    Hanby, Matthew F.
    McKenzie, Cameron R. L.
    Moe, Syed
    Dunlop, Adrian J.
    DRUG AND ALCOHOL REVIEW, 2023, 42 : S164 - S164
12345